# Immunic, Inc.: overview IMUX · Nasdaq · CIK 1280776 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/imux.md) · [Financials](/companies/imux/financials.md) · [Filings](/companies/imux/filings.md) · [Insiders](/companies/imux/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.24)](/filings/0001280776-25-000017.md) | not reported | [(2.51)](/filings/0001280776-26-000010.md) | [(2.03)](/filings/0001280776-26-000018.md) | [(0.13)](/filings/0001280776-25-000017.md) | not reported | [(1.08)](/filings/0001280776-26-000010.md) | [(0.80)](/filings/0001280776-26-000018.md) | | Free cash flow | $m | [(20.8) d](/filings/0001280776-25-000017.md) | [(23.0) d](/filings/0001280776-26-000005.md) | [(21.8)](/filings/0001280776-26-000010.md) | [(24.6) d](/filings/0001280776-26-000018.md) | [(20.2) d](/filings/0001280776-25-000017.md) | [(19.3) d](/filings/0001280776-26-000005.md) | [(17.3)](/filings/0001280776-26-000010.md) | [(31.2) d](/filings/0001280776-26-000018.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.93)](/filings/0001280776-23-000004.md) | [(3.78)](/filings/0001280776-24-000004.md) | [(2.11)](/filings/0001280776-25-000005.md) | [(1.00)](/filings/0001280776-26-000005.md) | [(0.62)](/filings/0001280776-26-000005.md) | | Free cash flow | $m | [(83.3)](/filings/0001280776-23-000004.md) | [(65.3)](/filings/0001280776-24-000004.md) | [(71.2)](/filings/0001280776-25-000005.md) | [(85.0)](/filings/0001280776-26-000005.md) | [(86.0)](/filings/0001280776-26-000005.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/imux/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $12.7m | 824,393 | | New +824,393 | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $11.8m | 765,295 | | New +765,295 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $11.4m | 740,347 | | New +740,347 | | [Avidity Partners Management LP](/funds/1791827.md) | 2026-06-30 | $10.3m | 669,941 | | New +669,941 | | [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $9.9m | 645,010 | | New +645,010 | | [Laurion Capital Management LP](/funds/1390202.md) | 2026-06-30 | $9.4m | 610,326 | | New +610,326 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.8m | 571,561 | | New +571,561 | | [Jones Hill Capital LP](/funds/2102314.md) | 2026-06-30 | $8.3m | 539,814 | | New +539,814 | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $7.2m | 471,528 | | New +471,528 | | [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $6.9m | 450,000 | | New +450,000 | ## Recent filings [All 824 filings](/companies/imux/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-11 | 21:24 ET | [8-K](/filings/0001193805-26-001219.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193805-26-001219 | | 2026-09-09 | 13:01 ET | [8-K](/filings/0001193805-26-001196.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193805-26-001196 | | 2026-08-11 | 11:05 ET | [8-K](/filings/0001193805-26-001071.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193805-26-001071 | | 2026-08-11 | 10:59 ET | [10-Q](/filings/0001280776-26-000018.md) | Quarterly report, period 2026-06-30 | 0001280776-26-000018 | | 2026-07-14 | 12:01 ET | [8-K](/filings/0001193805-26-000966.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193805-26-000966 | | 2026-07-06 | 20:22 ET | [8-K](/filings/0001193805-26-000916.md) | 5.02 Departure or appointment of officers or directors | 0001193805-26-000916 | | 2026-06-29 | 20:05 ET | [8-K](/filings/0001193805-26-000882.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193805-26-000882 | | 2026-05-29 | 20:33 ET | [DEF 14A](/filings/0001193805-26-000719.md) | Proxy statement, period 2026-06-29 | 0001193805-26-000719 | | 2026-05-28 | 11:01 ET | [8-K](/filings/0001193805-26-000703.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193805-26-000703 | | 2026-05-27 | 11:00 ET | [8-K](/filings/0001193805-26-000696.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193805-26-000696 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001280776-26-000005.md), filed Feb 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1280776 - Tickers: IMUX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.